HIV-specific immune responses in rabbits immunized with HIV-like particles and recombinant vaccinia virus.

Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

HIV-specific immune responses in rabbits immunized with HIV-like particles and recombinant vaccinia virus.

Int Conf AIDS. 1992 Jul 19-24;8(1):Mo13 (abstract no. MoA 0045). Unique Identifier : AIDSLINE ICA8/92400000
Hesselton RM; Mazzara GP; Panicali D; Sullivan JL; University of Massachusetts Medical School, Worcester.

Abstract: OBJECTIVES: To evaluate immune responses to a trivalent recombinant vaccinia virus vaccine which expresses three HIV-1 (IIIB) genes (env, gag, and pol). In addition we evaluated immune responses to HIV-1 pseudovirion particles produced in mammalian cells infected with the trivalent vaccine. METHODS: Rabbits were primed and boosted with combinations of the above described immunogens. Serum neutralizing assays were done against IIIB RF, and MN strains of HIV-1 as well as patient isolates. Neutralization was defined as 90% inhibition of p24 production. RESULTS: All rabbits developed strong antibody responses to core proteins as evidenced by Western blot analysis. Responses to env glycoproteins were weaker. Rabbits given both immunogens produced antibodies which neutralized the infectivity of HIV-1 (IIIB) in vitro. Neutralizing responses to several heterologous strains and patient isolates of HIV-1 were seen in rabbits immunized with the trivalent recombinant vaccinia virus and boosted with pseudovirion particles. A cellular system for evaluation of cytotoxic lymphocyte (CTL) responses was developed using homologous skin fibroblast cell lines as targets for CTL assays. CONCLUSIONS: A recombinant vaccinia virus vaccine expressing multiple HIV-1 genes along with pseudovirion particles derived from infected cells were used together to induce broad spectrum neutralizing antibodies. This trivalent vaccine is a candidate for a phase 1 trial in humans.

Keywords: Animal Antibody Specificity AIDS Vaccines/*IMMUNOLOGY Comparative Study Cytotoxicity Tests, Immunologic/METHODS Fibroblasts Genes, env Genes, gag Genes, pol HIV Antibodies/*BIOSYNTHESIS HIV-1/*IMMUNOLOGY Immunization Immunization, Secondary Neutralization Tests Rabbits/IMMUNOLOGY Vaccines, Synthetic/*IMMUNOLOGY Vaccinia Virus/IMMUNOLOGY Virion ABSTRACT
921230
M92C5347

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .